# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Cleopatra (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC003-SYN
- Date: 2026-05-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nefeli Arvanitis-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Prenatal visit at 19 weeks with the anatomy scans. **S**

## History of present illness

Cleopatra returns at 19 weeks 0 days. The nausea stopped about two weeks ago and she has not needed doxylamine with pyridoxine since. She takes aspirin at bedtime without bruising or bleeding, the prenatal vitamin, and ferrous sulfate every other day. She has more energy and has begun to feel movements. She has no bleeding, pain, tightenings, headache, or urinary symptoms. The cell-free DNA result was low risk for trisomies 21, 18, and 13. She had the detailed anatomy scans this morning. **S**

| Element | Detail |
|---|---|
| Nausea | Resolved |
| Screening | Cell-free DNA low risk |
| Fetal movement | First movements felt |
| Medicines | Aspirin, prenatal vitamin, ferrous sulfate every other day |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better |
| Gastrointestinal | Negative | No nausea, vomiting, or constipation |
| Genitourinary | Negative | No bleeding, leaking fluid, or urinary symptoms |
| Obstetric | Negative | No tightenings or pelvic pressure |

4 systems reviewed. **S**

## Current medications

- Prenatal vitamin containing folic acid 0.4 mg, one tablet by mouth daily **S**
- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/62 mmHg; pulse 88 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 61.5 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.1 g/dL; Ferritin: 24 ng/mL (low); Cervical length: 41 mm. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.8 g/dL (low) at baseline, 11.1 g/dL at this visit **S**
- Ferritin: 14 ng/mL (low) at baseline, 24 ng/mL (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Abdomen | Fundal height 22 cm, consistent with twins at 19 weeks; non-tender |
| Fetal | Scans: normal anatomy in both twins; fetal hearts 150 and 146 per minute |
| Placenta and cervix | Fused anterior placenta clear of the cervix; transvaginal cervical length 41 mm |
| Urine dipstick | Protein negative |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Twin pregnancy, dichorionic diamniotic** (O30.041). Normal anatomy in both twins; low-risk cell-free DNA; placenta clear of the cervix; cervical length 41 mm, which is reassuring. Blood pressure 104/62 mmHg. **S**
   - Continue aspirin.
   - Growth scan, blood count, and glucose challenge at 25 weeks.
   - Cervical length is not repeated routinely; any later measurement only for symptoms.
2. **Iron deficiency anemia in pregnancy** (O99.011). Hemoglobin 11.1 g/dL and ferritin 24 ng/mL: responding to oral iron, so intravenous iron is not needed. **S**
   - Continue ferrous sulfate every other day.
   - Recheck at 25 weeks.
3. **Nausea and vomiting of pregnancy** (O21.9). Resolved. **S**
   - Doxylamine with pyridoxine stopped.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 104/62 mmHg; urine protein negative |
| Examination | Fetal hearts and fundal height | Every prenatal visit | Completed today | Fetal hearts 150 and 146 per minute; fundal height 22 cm |
| Examination | Weight gain (about 17 to 25 kg for twins from a normal BMI) | Every prenatal visit | Completed today | 61.5 kg, up 3.5 kg since intake |
| Imaging | Detailed anatomy scans with placental location | At 18 to 22 weeks | Completed today | Normal anatomy in both twins; placenta anterior and clear of the cervix |
| Imaging | Cervical length | At the anatomy scan; routine serial screening is not supported in twins | Completed today | 41 mm by transvaginal scan |
| Laboratory | Cell-free DNA screening | From 10 weeks, as she chose | Completed today | Low risk for trisomies 21, 18, and 13 |
| Laboratory | Hemoglobin and ferritin | At intake, at the anatomy-scan visit, at 24 to 28 weeks, and in the third trimester | Completed today | Hemoglobin 11.1 g/dL and ferritin 24 ng/mL; responding to oral iron |
| Medication safety | Low-dose aspirin | Daily from 12 weeks until delivery; review at every visit | Completed today | Taken nightly since 12 weeks; no bruising or bleeding |
| Imaging | Growth scan with discordance | Every four weeks from about 20 to 24 weeks in a dichorionic twin pregnancy | Due | First growth scan booked at 25 weeks |
| Laboratory | Gestational diabetes screen | At 24 to 28 weeks | Due | At 25 weeks |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Due | Second-trimester screen at 25 weeks |
| Self-management | Preterm labor warning signs | Every prenatal visit | Completed today | Warning signs reviewed |

## Goal progress

- The cause of the large uterus and the dating of the pregnancy established at the 11-week scan. Outcome by 2026-03-17: Dichorionic diamniotic twins; dating by her last period confirmed by the crown-rump lengths. **S**
- An informed choice about aneuploidy screening by 14 weeks. Outcome by 2026-03-17: Chose nuchal translucency for each twin with cell-free DNA; declined diagnostic testing for now. **S**
- Hemoglobin and ferritin in the normal range for pregnancy by the third trimester. In progress; target 2026-08-18. **S**
- Growth discordance under 20 percent at every growth scan. In progress; target 2026-08-18. **S**
- A written delivery plan agreed by 34 weeks. In progress; target 2026-08-18. **S**

## Medication changes

- Stopped: Doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg delayed-release tablet, two tablets by mouth at bedtime **S**

## Guideline basis

- Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies: ACOG Practice Bulletin, Number 231 (2021), American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine (Obstetrics & Gynecology)
- Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234 (2021), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force

## Follow-up

- Prenatal visit with the growth scan, blood count, and glucose challenge at 25 weeks. **S**
- Next scheduled visit 2026-06-23: prenatal visit at 25 weeks: growth scan, glucose challenge, and blood count. **S**
